Alembic Pharmaceuticals Ltd
Please find attached Revised Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 02:51 PM IST · BSE ID: b0c5a53f-3d78-4d87-a7e8-d6747ae38f13
View Original BSE Filing (PDF)
💡
In Simple Terms
Alembic Pharmaceuticals announced its first-quarter financial results, showing significant growth in revenue and profit.
🤖 AI Summary
- Alembic Pharmaceuticals' Q1 FY27 consolidated revenue from operations grew 26% YoY to Rs. 2150 Cr.
- Profit After Tax for Q1 FY27 increased by 12% YoY, reaching Rs. 173 Cr.
- EBITDA pre R&D stood at Rs. 523 Cr in Q1 FY27, with a margin of 24%.
- US Formulation business revenue rose 49% to Rs. 778 Cr, and API business grew 33% to Rs. 346 Cr.
- India Branded Business reported 7% YoY growth, with revenue of Rs. 642 Cr for the quarter.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
Rs. 2150 Cr
26%
Profit After Tax (Q1 FY27)
Rs. 173 Cr
12%
EBITDA pre R&D (Q1 FY27)
Rs. 523 Cr
India Branded Business (Q1 FY27)
Rs. 642 Cr
7%
US Formulation (Q1 FY27)
Rs. 778 Cr
49%
Ex-US Generics (Q1 FY27)
Rs. 383 Cr
17%
API business (Q1 FY27)
Rs. 346 Cr
33%
🏢 How This Affects the Company
The company demonstrated broad-based growth across businesses, driven by healthy volume growth, new product launches, and execution in key markets, especially the US.
Increased revenue from operations and Profit After Tax indicate improved financial performance for the quarter, with EBITDA pre R&D margin at 24% reflecting operational efficiency.
Seven new product launches in the US market and three new product introductions in the India Branded Business demonstrate ongoing portfolio expansion and operational execution.
👥 What This Means For Shareholders
✅
Action Required
No action required based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with reported Q1 FY27 revenue up 26% to Rs. 2150 Cr and PAT up 12% to Rs. 173 Cr.
🔍
Management Signal
Management indicates focus on strengthening the product portfolio, advancing the pipeline, and driving sustainable long-term growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor sustained growth in US Formulation and API segments.
New product launches — observe impact of 7 US launches on international business.
Earnings call on August 04, 2026 — listen for management commentary on outlook.
LOW RISK
The filing indicates resilient performance across segments with notable growth.
💡 Investor Takeaway
Alembic Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs. 2150 Cr, up 26% YoY, and Profit After Tax of Rs. 173 Cr, up 12% YoY. US Formulation revenue increased 49% to Rs. 778 Cr.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated revenue from operations increased by 26% YoY to Rs. 2150 Cr, driven by strong performance across segments.
- US Formulation business grew by 49% to Rs. 778 Cr and API business by 33% to Rs. 346 Cr, showing robust international and manufacturing segment growth.
⚠️ Concerns
- India Branded Business growth was 7% YoY, reaching Rs. 642 Cr, lower than the overall revenue growth rate of 26%.
- Profit After Tax increased by 12% YoY to Rs. 173 Cr, growing at a slower rate than the 26% increase in revenue from operations.
📅 Company Track Record
Alembic Pharmaceuticals' previous Q1 FY27 filing (same day, same category) also highlighted consolidated revenue of Rs. 2,149.77 Crores and profit of Rs. 173.07 Crores, consistent with this revised press release.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Alembic Pharmaceuticals' consolidated revenue in Q1 FY27?
Alembic Pharmaceuticals reported consolidated revenue from operations of Rs. 2150 Cr in Q1 FY27, representing a 26% YoY increase.
What was Alembic Pharmaceuticals' Profit After Tax for Q1 FY27?
Profit After Tax for Alembic Pharmaceuticals in Q1 FY27 was Rs. 173 Cr, which is an increase of 12% YoY.
How much did Alembic Pharmaceuticals' US Formulation business grow in Q1 FY27?
The US Formulation business of Alembic Pharmaceuticals grew by 49% in Q1 FY27, reaching Rs. 778 Cr.
What was the growth of Alembic Pharmaceuticals' API business in Q1 FY27?
Alembic Pharmaceuticals' API business grew by 33% in Q1 FY27, generating revenue of Rs. 346 Cr.
What was the EBITDA pre R&D for Alembic Pharmaceuticals in Q1 FY27?
EBITDA pre R&D for Alembic Pharmaceuticals stood at Rs. 523 Cr in Q1 FY27, with a margin of 24%.
Questions based on this BSE filing only. For information purposes.